Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases
Opus Genetics hosted an R&D Science Forum highlighting its pipeline of five gene therapy programs targeting inherited retinal diseases, with cash runway expected to extend into 2029. Management detailed the clinical development strategy, expecting OPGx-RDH12 and OPGx-LCA5 dosing to begin in Q4 2026, followed by OPGx-MERTK in Q1 2027 and OPGx-RHO in the second half of 2027.
Key figures
- Cash runway
- into 2029
- Rho patients us
- 8800
- Lca5 patients us
- 170
- Best1 patients us
- 8400
- Mertk patients us
- 2600
- Rdh12 patients us
- 2500
- Rho patients global
- 30200
- Lca5 patients global
- 3240
- Best1 patients global
- 21800
- Mertk patients global
- 21960
- Rdh12 patients global
- 30900
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.